HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A resurgence of β-lactamase inhibitor combinations effective against multidrug-resistant Gram-negative pathogens.

Abstract
β-Lactamase inhibitors (BLIs) have played an important role in combatting β-lactam resistance in Gram-negative bacteria, but their effectiveness has diminished with the evolution of diverse and deleterious varieties of β-lactamases. In this review, a new generation of BLIs and inhibitor combinations is presented, describing epidemiological information, pharmacodynamic studies, resistance identification and current clinical status. Novel serine BLIs of major interest include the non-β-lactams of the diazabicyclo[3.2.1]octanone (DBO) series. The DBOs avibactam, relebactam and RG6080 inhibit most class A and class C β-lactamases, with selected inhibition of class D enzymes by avibactam. The novel boronic acid inhibitor RPX7009 has a similar inhibitory profile. All of these inhibitors are being developed in combinations that are targeting primarily carbapenemase-producing Gram-negative pathogens. Two BLI combinations (ceftolozane/tazobactam and ceftazidime/avibactam) were recently approved by the US Food and Drug Administration (FDA) under the designation of a Qualified Infectious Disease Product (QIDP). Other inhibitor combinations that have at least completed phase 1 clinical trials are ceftaroline fosamil/avibactam, aztreonam/avibactam, imipenem/relebactam, meropenem/RPX7009 and cefepime/AAI101. Although effective inhibitor combinations are in development for the treatment of infections caused by Gram-negative bacteria with serine carbapenemases, better options are still necessary for pathogens that produce metallo-β-lactamases (MBLs). The aztreonam/avibactam combination demonstrates inhibitory activity against MBL-producing enteric bacteria owing to the stability of the monobactam to these enzymes, but resistance is still an issue for MBL-producing non-fermentative bacteria. Because all of the inhibitor combinations are being developed as parenteral drugs, an orally bioavailable combination would also be of interest.
AuthorsKaren Bush
JournalInternational journal of antimicrobial agents (Int J Antimicrob Agents) Vol. 46 Issue 5 Pg. 483-93 (Nov 2015) ISSN: 1872-7913 [Electronic] Netherlands
PMID26498989 (Publication Type: Journal Article, Review)
CopyrightCopyright © 2015 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.
Chemical References
  • Anti-Bacterial Agents
  • beta-Lactamase Inhibitors
  • beta-Lactams
Topics
  • Anti-Bacterial Agents (therapeutic use)
  • Clinical Trials as Topic
  • Drug Discovery (trends)
  • Drug Therapy, Combination (methods)
  • Gram-Negative Bacteria (drug effects, enzymology)
  • Gram-Negative Bacterial Infections (epidemiology, microbiology)
  • Humans
  • beta-Lactamase Inhibitors (therapeutic use)
  • beta-Lactams (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: